RBC Capital analyst Anthony Codling lowered the firm’s price target on Amrize (AMRZ) to $54 from $61 but keeps an Outperform rating on the shares. Much of the share price weakness following Q2 results could have been avoided, but Amrize is paying the price of keeping a low profile, the analyst tells investors in a research note. RBC adds however that the guidance debate is a distraction that may lead investors to miss out on an attractive entry point in the Amrize story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ:
- Amrize Ltd Reports Q2 2025 Financial Results
- Amrize reports Q2 EPS 78c vs 86c last year
- Amrize sees FY25 revenue $11.4B-$11.8B, consensus $11.89B
- AI Daily: OpenAI to take cut of ChatGPT’s shopping sales
- Amrize, Meta Platforms partner on AI-optimized concrete mix